EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 35
- Locations
- 1
- Primary Endpoint
- Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection
Study Overview
Brief Summary
The COVID-19 pandemic highlights the importance of the prognosis of co-morbidities, such as coronary artery disease, which significantly increase the risk of mortality in patients infected with SARS-CoV2. Investigators have recently studied the complex links between respiratory infections, particularly pneumonia, and type 2 myocardial infarction (MI) in many respects. The etiology of type 2 MI is based on an imbalance of myocardial oxygen supply/need in the absence of rupture/erosion of atheromatous plaques. Based on the RICO survey data, the investigators investigated whether COVID-19-related sepsis and/or respiratory failure could be an underlying mechanism of MI2.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without pneumonia
- •patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without COVID 19
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection
Time Frame: Through study completion, an average of 1 year
Secondary Outcomes
No secondary outcomes reported